ZZL-7

Research use only, not for human use.

ZZL-7 is a fast-onset antidepressant agent that disrupts the interaction between neuronal nitric oxide synthase (nNOS) and the serotonin transporter (SERT) in the dorsal raphe nucleus (DRN).

ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD).

ZZL-7 (1.0 μM; or 2 h) incubation of the cultured 293T cells transfected with nNOS and SERT, significantly decreases the SERT-nNOS complex level.

ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time.Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment. ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment.Animal Model:SERT-Cre mice Dosage:10 mg/kg Administration:i.p.; once Result:Significantly increased firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice.

——

Others

Other Targets

Serotonin Transporter

——

——

99141-91-0

244.29

C11H20N2O4

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (1023.37 mM; Ultrasonic )

COC(=O)[C@@H](NC(=O)[C@H](C)NC(C)=O)C(C)C

——

(-20℃)

With Ice Pack

≥ 2 years